An ACE-I trial in stroke patients suggested that ACE-Is or angiotensin II receptor blockers in ICH patients result in less peri-haematomal oedema at 3 days, improve 3 month mortality and reduce rate of post-stroke pneumonia (Zhang et al., 2021). The gene discussed is ACE; the disease is stroke disorder.